ALX Oncology Q4 loss narrows, names permanent CMO

ALX Oncology Holdings

27/02/2026 13:07

Overview

Biotechnology firm reported decreased R&D expenses and net loss for Q4 2025

Company completed $150 mln registered offering, extending cash runway through 1H 2028

Barbara Klencke appointed as Chief Medical Officer on a permanent basis

Outlook

Company expects topline data from ASPEN-09 breast cancer trial by mid-2027

ALX Oncology plans to present evorpacept biomarker analysis at ESMO 2026

Company anticipates ALX2004 safety data in 2H 2026

Result Drivers

CLINICAL PROGRESS - ALX Oncology reported strong clinical development for evorpacept and ALX2004, with promising data in HER2-positive cancers

FINANCIAL STRATEGY - Co completed $150 mln equity offering, extending cash runway through 1H 2028 to support clinical programs

LEADERSHIP APPOINTMENT - Barbara Klencke appointed as Chief Medical Officer to strengthen clinical development

Company press release: ID:nGNX7j0VVM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.42
Q4 Net Income
-$22.85 mln
Q4 Basic EPS
-$0.42
Q4 Income from Operations
-$23.02 mln
Q4 Operating Expenses
$23.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $4.00, about 70.2% above its February 26 closing price of $2.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)